<DOC>
	<DOCNO>NCT02547792</DOCNO>
	<brief_summary>This phase 1 , single-center , placeb-controlled , double-blind study . The purpose study determine safety immunogenicity oral vaccine tablet prevent seasonal influenza B test two dose level ( low high dose ) . The study enroll 27 subject low dose cohort ( 3 sentinel open label subject follow 24 subject ( randomized 2:1 vaccine v placebo , respectively ) . Subsequently , 27 subject enrol high dose cohort similar manner low dose cohort . Safety immunogenicity evaluate Day 28 . Long term safety follow-up evaluate 1 year post vaccination .</brief_summary>
	<brief_title>Assessment Oral Influenza B Vaccine Tablet ( VXA-BYW.10 ) Following Single Dose Administration Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>In good health establish medical history , physical examination , laboratory test time enrollment . Positive B influenza HAI . Has influenza vaccine past 2 year . Current history chronic alcohol use and/or illicit and/or recreational drug use . History confirm suspected immunodeficient immunosuppressive condition Positive serology HIV , HCV , HBV Previous serious reaction vaccination anaphylaxis , respiratory problem , hive , abdominal pain . History irritable bowel disease inflammatory digestive gastrointestinal condition could affect intend distribution vaccine target mucosa small intestine Use proton pump inhibitor ( Nexium , Prilosec ) . Stool sample occult blood baseline exam Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Influenza B</keyword>
</DOC>